GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Milestone Pharmaceuticals Inc (NAS:MIST) » Definitions » Book Value per Share

Milestone Pharmaceuticals (Milestone Pharmaceuticals) Book Value per Share : $0.75 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Milestone Pharmaceuticals Book Value per Share?

Milestone Pharmaceuticals's book value per share for the quarter that ended in Mar. 2024 was $0.75.

During the past 12 months, Milestone Pharmaceuticals's average Book Value Per Share Growth Rate was -53.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -52.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Milestone Pharmaceuticals was -25.50% per year. The lowest was -52.90% per year. And the median was -39.20% per year.

Milestone Pharmaceuticals's current price is $1.75. Its book value per share for the quarter that ended in Mar. 2024 was $0.75. Hence, today's PB Ratio of Milestone Pharmaceuticals is 2.33.

During the past 7 years, the highest P/B Ratio of Milestone Pharmaceuticals was 3.74. The lowest was 1.16. And the median was 2.07.


Milestone Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Milestone Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Milestone Pharmaceuticals Book Value per Share Chart

Milestone Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial 4.69 4.80 3.77 1.94 0.50

Milestone Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.21 0.85 0.50 0.75

Competitive Comparison of Milestone Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Milestone Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Milestone Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Milestone Pharmaceuticals's PB Ratio falls into.



Milestone Pharmaceuticals Book Value per Share Calculation

Milestone Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(16.77-0.00)/33.48
=0.50

Milestone Pharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(39.92-0.00)/53.25
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Milestone Pharmaceuticals  (NAS:MIST) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Milestone Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Milestone Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Milestone Pharmaceuticals (Milestone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.
Executives
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
David Bharucha officer: Chief Medical Officer C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Debra K. Liebert director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6
Richard C Pasternak director C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6
Michael John Tomsicek director 28 OVERLOOK DRIVE, BEDFORD MA 01730
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jeffrey Edward Nelson officer: Chief Operating Officer C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Novo Holdings A/s 10 percent owner, other: SEE REMARKS TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Amit Hasija officer: CFO & EVP of Corp. Development C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6
Lorenz Muller officer: Chief Commercial Officer C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6

Milestone Pharmaceuticals (Milestone Pharmaceuticals) Headlines

From GuruFocus